New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
- ANP Technologies
- 824 Interchange Boulevard
- Newark DE, 19711
- UNITED STATES
We are rapidly gaining a reputation as the “go-to” firm that large pharmaceutical and biotechnology companies come to when encountering obstacles in developing new biological drugs. Our company has one of the most experienced scientific staffs in the industry, when it comes to working with protein-related compounds. From our groundbreaking work with measuring the immunogenicity of large molecules to pharmacokinetics to our un-paralleled ability to generate significantly higher yields of antibodies through affinity purification, ANP Technologies® stands at the forefront of innovative technologies.